Acetaminophen (APAP) also known as paracetamol and Tylenol is a widely used anti-analgesic and antipyretic that has been used in therapeutic practice for over a century. It’s commonly used to treat headaches, toothaches, osteoarthritic pain, and even post-operative pain [1]. For a drug that is so widely used, the exact mechanism of action is still a mystery. However, different studies have led to the widespread belief that acetaminophen acts on the central serotonergic system to provide analgesic effects. Pickering et al. concluded through a clinical trial that co-administration of hydroxytryptamine type 3 antagonists such as tropisetron (5 mg) and granisetron (3 mg) with acetaminophen (1 mg) blocks the anti-analgesic impact of acetaminophen on the central serotonergic system [2]. Acetaminophen has been shown to penetrate the blood-brain barrier in humans, according to research [3]. As a result, it further strengthens the idea that APAP has a relationship to the serotonergic system. When taken as prescribed, acetaminophen is well tolerated; nevertheless, hypersensitivity, nephrotoxicity, and pancytopenia are some of the side effects of orally or rectally administered APAP. Nausea, vomiting, constipation, stomach pain, and pruritus are all possible side effects of intravenous APAP [4]. Acetaminophen (APAP) overdose is linked to hepatotoxicity and acute liver failure [5]. The FDA-approved standard antidote for APAP overdose is N-acetyl cysteine. According to recent findings, fomepizole could be used as an additional antidote for APAP poisoning [6].

A recent study presented in the annual meeting of the American Society of Clinical Oncology and later published in the Journal of Annals of Oncology in May 2022 raised new and more serious concerns — it revealed that cancer patients who take acetaminophen as pre-medication have a much-reduced response to immunotherapy. Immuno-therapy works by blocking immune checkpoints, which enable immune cells to fight cancer more effectively [7]. In a study, 600 patients with advanced cancer were given acetaminophen before starting immunotherapy, and the response of immune checkpoint inhibitors was assed after the immunotherapy was started. The response of immune checkpoint inhibitors was dramatically reduced, implying that acetaminophen (APAP) has immunosuppressive effects [6]. Acetaminophen (APAP) is frequently used to manage cancer-associated pain. A recent study looked at the effects of acetaminophen on cancer patients who were taking immune check inhibitors (ICB) [8]. T cells can destroy tumor cells by blocking the binding of checkpoints which enable immune cells to fight cancer more effectively. T cells can destroy tumor cells by blocking the binding of checkpoint proteins like PD1L to PD1 with immune checkpoint blockers [7]. The effects of acetaminophen on a preclinical tumor model (MC38) revealed that it significantly reduced the potency of ICB [9]. According to another study, acetaminophen therapy followed by interferon-gamma (20 ng/ml) for 2 h was linked to immune checkpoint PD1L expression stimulation [10]. Various other researchers have struggled to explain why acetaminophen suppresses the immune system. According to Neil et al. Aspirin and acetaminophen were tightly related to the reduction of the serum neutralizing antibody response towards the study challenge virus, Rhinovirus type 2. Ibuprofen had a weaker effect on antibody levels, and it did not differ significantly from placebo [11]. Another identical research concluded that acetaminophen helps increase the duration of varicella infections in children, supporting the idea that acetaminophen reduces the human immune system [12] Paracetamol is given prophylactically before or shortly after the vaccination to reduce the pain and fever associated with vaccinations. However, new research has revealed that such prophylactic treatment may be interfering with the development of an immune response to vaccine antigens [13]. When acetaminophen is administered prophylactically, it diminishes the response of Hepatitis B Antibodies (Anti-HBs) to Hepatitis B vaccination in adults. According to a study Anti-HBs levels in the group receiving therapeutic paracetamol were found to be comparable to those in the control group a month after the second booster was administered. However, Anti HBs levels were noticeably lower in the paracetamol group is given as a preventive [14].

Najeebullah a, Maria Ameer Ali a, Rida Naveed a, Govinda Khatri a, Priya a, Mohammad Mehedi Hasan b, a

a Dow University of Health Sciences, Karachi, Pakistan
b Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh

https://doi.org/10.1016/j.amsu.2022.104272
Received 14 July 2022; Accepted 20 July 2022
Available online 31 July 2022
2049-0801/© 2022 Published by Elsevier Ltd on behalf of LJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
It was also revealed from Animal trials that acetaminophen (APAP) decreases the antibody response towards Sheep red blood cells (SRBC) in both fed and fasted mice indicating acetaminophen has an immuno-suppressive impact on humoral immunity [15].

In light of these studies, the question still stands: Is acetaminophen safe to be considered as a premedication drug before initiating immunotherapy in patients with advanced cancer? The aforementioned studies are of chief importance and it is concerning because acetaminophen is still the first-line strategy to manage mild-to-moderate pain among patients with advanced cancer. The data provided highlights something that could dramatically change the way we manage our patients who are on immune check inhibitors. Health workers should use acetaminophen with care in patients who are on immunotherapy.

Ethical approval
NA.

Sources of funding
NA.

Author contribution
All authors meet the inclusion criteria, and all authors read and approved the final version of the manuscript.

Trail registry number
1. Name of the registry: NA.
2. Unique Identifying number or registration ID: NA.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): NA.

Guarantor
Mohammad Mehedi Hasan.
Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, 1902, Bangladesh.
Email: mehedi.bmb.mbstu@gmail.com.

Annals of medicine and surgery
The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

Consent
NA.

Declaration of competing interest
NA.

Acknowledgment
None.

References
[1] Paracetamol - Tests & treatments | NHS inform, (n.d.). https://www.nhsinform.scot/tests-and-treatments/medicines-and-medical-aids/types-of-medicine/paracetamol#:~:text=It%20%20typically%20used%20to%20relieve,ann%20side%20effects%20are%20rare accessed (accessed July 1, 2022).
[2] G. Pickering, M.A. Loriot, F. Libert, A. Eschaller, P. Benaue, C. Dubray, Analogic effect of acetaminophen in humans: first evidence of a central serotoninergic mechanism, Clin. Pharmacol. Ther. 79 (2006) 371–378, https://doi.org/10.1016/J.CLPT.2005.12.307.
[3] B. Bannwarth, P. Netter, F. Lapicque, P. Gillet, P. Pere, E. Boccard, R. Royer, A. Guicher, Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol, Br. J. Clin. Pharmacol. 34 (1992) 79–81, https://doi.org/10.1111/J.1365-2125.1992.TB04112.X.
[4] A. Ramachandran, H. Jaeschke, Acetaminophen, Liver Pathophysiology: Therapies and Antioxidants, 2021, pp. 101–112, https://doi.org/10.1016/B978-0-12-804274-8.00006-0.
[5] Z. Cai, B. Wang, Z. Zhou, X. Zhao, L. Hu, Q. Ren, L. Deng, Z. Li, G. Wang, Discovery and characterization of a novel and orally active Farnesoid X receptor agonist for the protection of acetaminophen-induced hepatotoxicity, Chem. Biol. Drug Des. 99 (2022) 483–495, https://doi.org/10.1111/CBDD.14014.
[6] A.M. Pourbagher-Shahri, J. Schimmel, F.M. Shirazi, S. Nakhaee, O. Mehrpour, Use of fomipeside (4-methylpyrazole) for acetaminophen poisoning: a scoping review, Toxicol. Lett. 355 (2022) 47–61, https://doi.org/10.1016/J.TOXLET.2021.11.005.
[7] Immunotherapy for Cancer - NCI, n.d. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy, (Accessed 1 July 2022).
[8] A. Besede, A. Marabelle, J.P. Guegan, F.X. Danlos, S. Cousin, F. Peyraud, N. Chaput, M. Spalato, G. Roubaud, M. Cabart, M. Khettab, A. Chaibi, C. Rey, I. Nafia, F.X. Mahon, J.C. Soria, A. Italiano, Impact of acetaminophen on the efficacy of immunotherapy in cancer patients, Ann. Oncol. (2022), https://doi.org/10.1016/J.ANOCL.2022.05.010.
[9] Acetaminophen Linked to Diminished Response to Immunotherapy in Cancer, (n.d.). https://www.medscape.com/viewarticle/975219, (Accessed 1 July 2022).
[10] J. Wu, A.J. Neuwell, L.L. Muldoon, E.A. Neuwell, Abstract A87: acetaminophen pretreatment stimulated interferon γ-induced PD-L1 protein expression in vitro and CD68 positive macrophage infiltration in tumor xenograft, Canc. Immunol. Res. 8 (2020), https://doi.org/10.1158/2326-6074.TUMIMM18-A87. A87–A87.
[11] N.M.H. Graham, C.J. Burrell, P. Debelle, L. Davies, R.M. Douglas, Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers, J. Infect. Dis. 162 (1990) 1277–1282, https://doi.org/10.1093/INFDIS/162.1.1277.
[12] T.F. Doran, C. de Angelis, F.X. Danlos, S. Cousin, F. Peyraud, N. Chaput, M. Spalato, G. Roubaud, M. Cabart, M. Khettab, A. Chaibi, C. Rey, I. Nafia, F.X. Mahon, J.C. Soria, A. Italiano, Impact of acetaminophen on the efficacy of immunotherapy in cancer patients, Ann. Oncol. (2022), https://doi.org/10.1016/J.ANOCL.2022.05.010.
[13] J. Wysocki, K.J. Center, J. Brzostek, E. Majda-Stanislawska, H. Szymanski, L. Szenborn, H. Czaja, B. Hasiec, J. Dziduch, T. Jackowska, A. Witor, E. Kopinska, R. Konior, P.C. Giardina, V. Sundarajyer, S. Patterson, W.C. Gruber, D.A. Scott, A. Gurtman, A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations, Vaccine 35 (2017), https://doi.org/10.1016/J.VACCINE.2017.02.035, 1926–1935.
[14] A.M.C.M. Doedee, G.J. Boland, J.L.A. Pennings, A. de Klerk, G.A.M. Berbers, F.R. van der Klis, H.E. de Melker, H. van Loveren, R. Janssen, Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials, PLoS One 9 (2014), https://doi.org/10.1111/J.1365-2125.1992.TB04112.X.
[15] K. Yasumura, K. Oyakawa, T. Yonekawa, T. Nakamura, S. Yano, K. Ueno, Inhibition of the antibody production by acetaminophen independent of liver injury in mice, biological and pharmaceutical bulletin. https://doi.org/10.1248/JIPB.25.201, 2002, 25, 201-205.